Literature DB >> 3760036

Phenotypic characterization of Ewing sarcoma cell lines with monoclonal antibodies.

M Lipinski, K Braham, I Philip, J Wiels, T Philip, K Dellagi, C Goridis, G M Lenoir, T Tursz.   

Abstract

The histogenesis of Ewing sarcoma, the second most frequent bone tumor in humans, remains controversial. Four Ewing cell lines were analyzed by immunological methods. A panel of antibodies directed to T, B, and myelomonocytic markers gave negative results. Surface antigens recognized on Ewing cells were found to be related to the neuroectoderm lineage. Ganglioside GD2, a marker of neuroectodermal tissues and tumors, was present on all lines. These were also stained by the mouse monoclonal antibody HNK-1, which detects a carbohydrate epitope present on several glycoconjugates of the nervous system, including two glycoproteins, the myelin-associated glycoprotein and the neural cell-adhesion molecule (N-CAM), and an acidic glycolipid of the peripheral nervous system. The P61 monoclonal antibody, which reacts with a peptide moiety of N-CAM, and a rabbit antiserum, raised to purified mouse N-CAM and not recognizing the HNK-1-defined epitope, were also reactive. By contrast, all antibodies specific for hematopoietic cell surface antigens were totally negative. Besides these antigenic features, Ewing sarcoma cells are characterized by a specific t(11;22)(q24;q12) translocation also observed in neuroepithelioma, a neuroectodermal tumor, suggesting a possible evolutionary related origin. The recent finding that the human N-CAM gene is located at the vicinity of the breakpoint on chromosome 11 indicates that it might be involved in genetic rearrangements occurring in this region.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3760036     DOI: 10.1002/jcb.240310406

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  9 in total

1.  Oncotargets GD2 and GD3 are highly expressed in sarcomas of children, adolescents, and young adults.

Authors:  Konstantin Dobrenkov; Irina Ostrovnaya; Jessie Gu; Irene Y Cheung; Nai-Kong V Cheung
Journal:  Pediatr Blood Cancer       Date:  2016-06-15       Impact factor: 3.167

Review 2.  Recent advances in the molecular pathogenesis of Ewing's sarcoma.

Authors:  E C Toomey; J D Schiffman; S L Lessnick
Journal:  Oncogene       Date:  2010-06-14       Impact factor: 9.867

Review 3.  Targeted therapies for advanced Ewing sarcoma family of tumors.

Authors:  Yunyun Jiang; Joseph Ludwig; Filip Janku
Journal:  Cancer Treat Rev       Date:  2015-03-27       Impact factor: 12.111

4.  Induction of glycogenolysis in cultured Ewing's sarcoma cells by dopamine and beta-adrenergic agonists.

Authors:  F van Valen; E Keck
Journal:  J Cancer Res Clin Oncol       Date:  1988       Impact factor: 4.553

5.  Immunocytochemical analysis of Ewing's tumors. Patterns of expression of intermediate filaments and desmosomal proteins indicate cell type heterogeneity and pluripotential differentiation.

Authors:  R Moll; I Lee; V E Gould; R Berndt; A Roessner; W W Franke
Journal:  Am J Pathol       Date:  1987-05       Impact factor: 4.307

6.  Tissue microarrays: applications in study of p16 and p53 alterations in Ewing's cell lines.

Authors:  Rosa Noguera; Isidro Machado; Marta Piqueras; Jose Antonio Lopez-Guerrero; Samuel Navarro; Empar Mayordomo; Antonio Pellin; Antonio Llombart-Bosch
Journal:  Diagn Pathol       Date:  2008-07-15       Impact factor: 2.644

7.  Epitope detection in monocytes (EDIM) for liquid biopsy including identification of GD2 in childhood neuroblastoma-a pilot study.

Authors:  Matias J Stagno; Andreas Schmidt; Steven W Warmann; Evi Schmid; Jonas Bochem; Cristian Urla; Rupert Handgretinger; Karin M Cabanillas Stanchi; Rafael Saup; Manon Queudeville; Jörg Fuchs
Journal:  Br J Cancer       Date:  2022-07-21       Impact factor: 9.075

8.  Effective combination treatment of GD2-expressing neuroblastoma and Ewing's sarcoma using anti-GD2 ch14.18/CHO antibody with Vγ9Vδ2+ γδT cells.

Authors:  Jonathan P H Fisher; Barry Flutter; Florian Wesemann; Jennifer Frosch; Claudia Rossig; Kenth Gustafsson; John Anderson
Journal:  Oncoimmunology       Date:  2015-04-27       Impact factor: 8.110

Review 9.  A Novel Treatment for Ewing's Sarcoma: Chimeric Antigen Receptor-T Cell Therapy.

Authors:  Zili Lin; Ziyi Wu; Wei Luo
Journal:  Front Immunol       Date:  2021-09-10       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.